Komori
M&A and Subsidiary Changes4883Modalis Therapeutics CorporationPharmaceuticals

Notice Regarding the Transfer of Fixed Assets by a Consolidated Subsidiary and the Recognition of Extraordinary Gain

The consolidated subsidiary has decided to dispose of idle machinery and equipment and other assets it owns, and plans to recognize an approximately ¥17.5 million gain on the sale of fixed assets as an extraordinary gain in the fiscal year ending December 2026. The disposal price and book value have not been disclosed.

Worth reading
39Recurring
Scored from 3 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
17500
¥ thousand (approximate gain on disposal)
Wording
Conditional
How definitive the wording is.

This transaction

Disposal of Fixed Assets
TimelineThe spacing between the points is proportional to the actual number of days.
Consideration and expenses
Acquisition priceThe disposal price has not been disclosed at the request of the transferee.
Expenses other than the acquisition priceVarious expenses related to the disposal (amount not disclosed)
Amount of extraordinary income (loss)The company plans to recognize an approximately ¥17.5 million gain on the sale of fixed assets as an extraordinary gain in its financial statements for the fiscal year ending December 2026.
Impact on Business Performance

The impact on financial results is expected to be immaterial.

Procedures and assumptions
Valuation methodologyFair price reflecting market prices (specific valuation method not stated)
This transaction
ItemDetails
Transaction nameDisposal of Fixed Assets
Acquisition priceThe disposal price has not been disclosed at the request of the transferee.
Expenses other than the acquisition priceVarious expenses related to the disposal (amount not disclosed)
Amount of extraordinary income (loss)The company plans to recognize an approximately ¥17.5 million gain on the sale of fixed assets as an extraordinary gain in its financial statements for the fiscal year ending December 2026.
Impact on Business PerformanceThe impact on financial results is expected to be immaterial.
Date of board resolution27 April 2026
Contract Date30 April 2026 (scheduled)
Execution Date / Effective Date8 May 2026 (scheduled)
Valuation methodologyFair price reflecting market prices (specific valuation method not stated)
Items this document does not state (23)
Counterparty nameName of the Subject CompanyBusiness Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To improve the efficiency of management resources, make effective use of assets, and replace and optimize assets that have become idle after completing their role due to advances in process development.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Transfer of Fixed Assets by a Consolidated Subsidiary and the Recognition of Extraordinary Gain | Modalis Therapeutics Corporation (4883) timely disclosure | Komori